Squarepoint’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Squarepoint’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-35,697	Closed	-$150K	–	2462
2018 Q3	$150K	Buy	35,697 +20,092	+129%	+$84.7K	﹤0.01%	1830
2018 Q2	$60K	Buy	+15,605	New	+$104K	﹤0.01%	1682
2017 Q3	–	Sell	-4,646	Closed	-$45K	–	2049
2017 Q2	$45K	Buy	+4,646	New	+$94.9K	﹤0.01%	1462
2017 Q1	–	Sell	-4,141	Closed	-$133K	–	2161
2016 Q4	$133K	Buy	+4,141	New	+$177K	0.01%	1574
2016 Q2	–	Sell	-3,152	Closed	-$208K	–	1483
2016 Q1	$208K	Sell	3,152 -4,677	-60%	-$244K	0.02%	985
2015 Q4	$486K	Buy	+7,829	New	+$551K	0.05%	557

Other funds holding MACK

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Sepio Capital Salt Lake City, Utah $1.84B AUM 18.57% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

WIM

Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Squarepoint's MACK Position: Q4 2018 in Review

Squarepoint sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2018, closing a stake of 35,697 shares — an estimated $150K sold.

Squarepoint first reported a position in MACK in Q4 2015 and held it in 6 quarters. The position peaked at $486K in Q4 2015. 56 funds tracked by Wall St. Rank hold MACK as of Q4 2018.

Squarepoint reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
Squarepoint sold 35,697 Merrimack Pharmaceuticals, Inc. shares in Q4 2018, an estimated $150K.
Squarepoint first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2015 and held it in 6 quarters.
Squarepoint's Merrimack Pharmaceuticals, Inc. position peaked at $486K in Q4 2015.
56 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2018.

Based on Squarepoint's 13F filing for Q4 2018, filed 14 Feb 2019.